Subconjunctival interleukin-1 receptor antagonist inhibits graft rejection following high-risk penetrating keratoplasty in rats

Abstract

Abstract: Objective To observe the roles of subconjunctival administration of interleukin-1 receptor antagonist (IL-1ra) promoting corneal graft survival in rat models of high-risk penetrating keratoplasty. Methods Corneal vascularization was induced in 40 Sprague-Dawley rats (40 eyes) by passing 10-0 silk suture through the corneal stroma, and 30 of these rats received corneal grafts from Wistar rats to establish high-risk keratoplasty models and were divided into 3 groups to receive their respective treatment with IL-1ra eye drops (50 μg/ml), 1% CsA eye drops, administered 3 times a day, or no treatment. All the rats were treated by Tobra Dex eye drops and Tropicamid eye drops, 3 times a day for 14 consecutive days after the operation. During the 30-day observation, the survival of the grafts was recorded, and all the grafts were evaluated for signs of rejection. Results The mean survival times (MST) of the grafts of the treatment groups with IL-1ra and CsA were 12.00±1.50 d and 10.44±1.13 d respectively, significantly longer than that in the untreated model group (8.00±1.25 d, t=0.00, P<0.01), and the difference in the MST between the 2 treatment groups was also significant (t=0.00, P<0.01). Conclusion Treatment with IL-1ra may significantly prolong high-risk corneal allograft survival.

CLC Number:

R779.65

ZHOU Jin, LU Xiao-he, DANG Sen-tao, BAI Lang, ZHANG Yong-qiang, XU Ning. Subconjunctival interleukin-1 receptor antagonist inhibits graft rejection following high-risk penetrating keratoplasty in rats[J]. Journal of Southern Medical University, 2004, 24(05): 539-541.

References

[1] Coster DJ. Mechamisms of corneal graft failure; the erosion of corneal privilege[J]. Eye, 1989, 3(2): 151-3.
[2] Apel A, Oh C, Chiu R, et al. A subconjunctival degradable implant for cyclosporine delivery in corneal transplant therapy[J]. Curr Eye Res, 1995, 14(8): 659-67.
[3] Larkin DFP, Calder VL, Lightman SL. Identification and characterization of cells infiltrating the graft and aqueous humour in rat corneal allograft rejection[J]. Clin Exp Immunol, 1997, 107(2): 381-91.
[4] 吕岚,张文华,孙旭光.FK-506抑制大鼠角膜移植排斥反应的研究[J].中华眼科杂志,1999,35(1):25-8.LüL, Zhang WH, Sun XG. Experimental studies on the effect of the immunosuppressant FK 506 on penetrating keratoplasty rejection model in rats[J]. Chin J Ophthalmol, 1999, 35(1): 25-8.
[5] Dana MR, Zhu SN, Yamada J. Topical modulation ofinterleukin-1 activity in corneal neovascularization [J]. Cornea, 1998, 17(4): 403-9.
[6] BenEzra D, Hemo I, Mafizir G. In vivo antigenic activity of interleukins[J]. Arch Ophthalmol, 1994, 108(5): 573-6.
[7] Hannum CH, Wilcox CJ, Arend WP, et al. Interleukin-1 receptor antagonist activity of a human interleukin- 1 inhibitor [J]. Nature, 1990,343(6256): 336-40.
[8] 翟长斌,张文华,邹留河,等.白细胞介素-l受体拮抗剂防治角膜移植免疫排斥反应的实验研究[J].中华眼科杂志,2001,37(4):270-2.Zhai CB, Zhang WH, Zou LH, et al. An experimental study on subconjunctival interleukin-1 receptor antagonist for promotion of corneal transplant survival [J]. Chin J Ophthalmol, 2001, 37(4):270-2.
[9] 郭金华,查家华,陈国苍.IL-1ra对大鼠角膜移植免疫排斥反应的抑制作用[J].眼科研究,2001,19(3):195-7.Guo JH, Zha JH, Chen GC. The effects of IL-lra on penetrating keratoplasty rejection in rat[J]. Chin Oph Res, 2001, 19(3): 195-7.